Published in AIDS Weekly, April 21st, 2003
In an invited presentation at the 4th International Antiviral Drug Discovery and Development Summit in Princeton, New Jersey, the company described its plans to expedite development of PA-457, which is the first in a new class of HIV drugs called maturation inhibitors. Panacos scientists and their collaborators have demonstrated that PA-457 selectively blocks the last step in HIV maturation, a process that occurs as the virus buds from infected cells. Following PA-457 treatment, the released virus particles have a defective core structure and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.